Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Total Non-Current Liabilities (2024 - 2025)

Humacyte has reported Total Non-Current Liabilities over the past 2 years, most recently at $101.8 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $101.8 million for Q4 2025, down 14.9% from a year ago — trailing twelve months through Dec 2025 was $101.8 million (down 14.9% YoY), and the annual figure for FY2025 was $101.8 million, down 14.9%.
  • Total Non-Current Liabilities for Q4 2025 was $101.8 million at Humacyte, up from $96.0 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for HUMA hit a ceiling of $133.8 million in Q2 2025 and a floor of $92.8 million in Q1 2024.